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Many people who have cirrhosis are undiagnosed. The diagnosis may not become evident until they develop multiorgan failure
after an invasive procedure. Patients with cirrhosis are unusually fragile and can be easily harmed and even set into a fatal down-
spiral by seemingly innocuous treatments including medications and invasive procedures. There is much confusion regarding the
care of these patients. For example, what medications can be used safely to treat pain, what sedatives are safe and eﬀective, which
medications are to be avoided, what diet should be prescribed, and which invasive procedures are safe. This paper provides the
author’s advice regarding clues to the presence of cirrhosis and the dos and do nots in the general care of these patients, based on
his 30 years of experience in a liver-failure-focused academic practice.
1.Introduction
Cirrhosis is increasing in prevalence due to the epidemics
of hepatitis C and obesity and the associated fatty liver [1].
Alcohol use/abuse is increasing in many countries, in part
due to the global recession [2]. Many patients with cirrhosis
at this time have two or even all three of the above insults
speeding liver damage and scarring. It is estimated that there
may be 10,000,000 people with cirrhosis in the US, ∼3% of
the population. Many if not most of these patients are not
diagnosed yet with cirrhosis. Many exhibit signs or clues to
the presence of cirrhosis (Table 1). Physicians should be alert
to these signs and clues and then take the necessary steps to
evaluate them or refer them for evaluation and avoid causing
harm.
2. Clues to the Presence of Cirrhosis
Somecluesfortheprimarycareproviderorthespecialistthat
cirrhosis may be present can be found in a careful history,
physical examination, routine laboratory testing, and imag-
ing. The author is amazed how commonly these useful clues
are ignored.
Family medicine physicians and general internists should
be suspicious of the presence of cirrhosis in their patients
with metabolic syndrome and/or long-standing diabetes [3].
Many of these patients will have silent cirrhosis due to non-
alcoholic steatohepatitis (NASH).
Many people who abuse alcohol and/or drugs also
smoke. Pulmonologists and ear, nose, and throat specialists
should be alert to the possibility of cirrhosis in their patients
with chronic lung disease, lung cancer, or head and neck
cancer.Tooofteninvasive,curativeproceduresareperformed
to treat cancer, without recognition that cirrhosis is present;
and the patient dies tumor-free, but is dead nonetheless.
Preoperative assessment of the risks versus beneﬁts of an
invasive procedure is much more accurate once the presence
of cirrhosis is known or suspected. Referral of the patient to
a hepatologist for pre-operative “clearance” is wise. A less
invasive procedure may be recommended. The patient may
bemorelikelytosurvivealessinvasiveprocedureratherthan
the state-of-the-art aggressive procedure.
3. History
Risk factors for cirrhosis include long-standing obesity
(especially if insulin resistance or overt diabetes is present),2 International Journal of Hepatology
Table 1: Clues to the presence of cirrhosis.
Risk factors for liver disease, especially obesity, alcohol use, and
high-risk behavior for hepatitis C
Sleep/wake reversal
History of ﬂuid retention, gastrointestinal hemorrhage, or
unexplained episodic confusion
Stigmata of cirrhosis, including palmar erythema, vascular
spiders, and abdominal wall collaterals
Firm liver and/or enlarged spleen
Jaundice, ascites, or asterixis
Platelet count <160,000 × 10(9)/L
Abnormal liver tests
Prolonged international normalized ratio (INR)
Evidence of cirrhosis and/or portal hypertension on imaging
Unusual sensitivity to coumadin
chronic alcohol use (>14 drinks/week for women and >28
drinks/week for men), transfusion prior to 1992, and street
drug use [4]. Many patients who have shared needles in
the use of drugs, with resulting hepatitis C, are reluctant to
divulge this information but may admit to cocaine snorting
or other drug use. Tattoos and acupuncture can transmit
hepatitis C or B, although the risk is not very high. Birth in
Southeast Asia, areas in South America, or Africa is a risk
factor for hepatitis B. Hepatitis C is hyperendemic in Italy,
Egypt, other parts of the Middle East, Vietnam, and Japan.
Children who have lived in chronic care facilities are at risk
for hepatitis B due to biting and other activities that occur in
these institutions. Sexual promiscuity, especially in men who
have sex with men, is high risk for hepatitis B [4].
Sleep/wake reversal commonly precedes overt hepatic
encephalopathy (HE). Standard medications for insomnia
regularly unmask the tendency for confusion and can bring
on frank coma.
A history of abdominal enlargement and/or edema, ep-
isodic confusion, or bleeding from the gut should all raise
strong suspicion of cirrhosis.
4.PhysicalExamination
Palmarerythema,vascularspiders,andabdominalcollaterals
are useful to look for on physical examination. Their pres-
ence should raise suspicion of cirrhosis. Parotid enlargement
is more common in alcohol abusers than in patients with
nonalcoholic liver disease and is not speciﬁc for liver disease.
A ﬁrm liver or palpable spleen also raises suspicion of cir-
rhosis. A past president of the American Association for the
Study of Liver Diseases used to say: “one good feel of the liver
is better than any two liver tests.” This is a very insightful
statement.
The presence of jaundice, ascites (with or without ede-
ma), or asterixis provides evidence of advanced liver injury.
5.LaboratoryTesting
Eugene Schiﬀtellsusthathe“hasgreatrespectfortheplatelet
count”asaclueforthepresenceofcirrhosis;thisisalsoavery
insightful statement. Almost everyone has a platelet count in
their medical database whether liver disease is suspected or
not. A platelet count <160,000 × 10(9)/L is 80% sensitive
in detecting portal hypertension from cirrhosis in patients
with chronic hepatitis C [5]. The white blood cell count may
also be below the normal range, but this is less common than
the thrombocytopenia of cirrhosis. Anemia (∼6.5 mmoL/L)
may be present when ascites develops, but hemoglobin may
be normal prior to decompensation.
Any patient with a platelet count <160,000 × 10(9)/L
should be suspected of having cirrhosis, especially if there is
other evidence of liver disease in the history, physical exami-
nation, or laboratory testing.
Many anesthesiologists will postpone/cancel an invasive
procedurewhentheplateletcountisbelowthenormalrange.
The optimal normal range can be debated; however, a value
below 160,000 is a very useful parameter in this author’s
experience—to cancel the procedure and request a hepa-
tology consult. It is also this author’s experience that in
relatively healthy outpatients, thrombocytopenia is more
common in the setting of liver disease than it is in primary
hematologic conditions. Although hematology consultation
is common in these patients, it is usually unnecessary and
simply delays evaluation by the hepatologist.
Fatty liver is extremely common now in the US and in
many other developed countries and is the usual explanation
foranabnormalaspartateaminotransferase(AST)oralanine
aminotransferase (ALT) [6]. An amazing 58% of Hispanics,
44% of Whites, and 35% of African Americans had fatty liver
by biopsy after initial ultrasound detection of steatosis in an
army medical clinic in Texas [7]. A variable percent of these
patients have abnormal aminotransferases. Approximately
20% of patients with fatty liver will develop cirrhosis in 20
years time [8]. The usual pattern of aminotransferases in
precirrhoticfattyliverisALT>AST.Oncecirrhosisdevelops,
this pattern may reverse.
When the alkaline phosphatase and/or bilirubin are also
elevated, liver disease is essentially assured and an evaluation
of the cause and severity is in order.
Blood urea nitrogen is regularly below the normal range
in patients with cirrhosis, and the international normalized
ratio (INR) is regularly increased. The INR, creatinine, and
bilirubin arethe components ofthe model forend-stageliver
disease (MELD) score, which quantiﬁes severity of cirrhosis
and prognosis [9].
6.Imaging
Generalists tend to order computed tomographic (CT) scans
in pursuit of abdominal pain or other abdominal pathology.
Hepatologists tend to perform or order ultrasounds initially
andthenorderaCTscanoncecirrhosisissuspectedonultra-
sound. CT appears much more sensitive than ultrasound in
detecting hepatocellular carcinoma.
Imaging without mention of a speciﬁc maximum spleen
dimension is not very useful. This author usually orders an
“ultrasound of the liver and spleen with Doppler.” If the
spleen dimension is not included in the report, this author
asks the radiologist to provide this crucial information.International Journal of Hepatology 3
Although many radiologists use 13cm as the threshold for
splenomegaly, this author has seen many patients, with
cirrhosis and portal hypertension, whose spleen was between
12 and 13cm. It is this author’s opinion that 12cm should be
the threshold to diagnose splenomegaly and raise suspicion
of cirrhosis with portal hypertension.
Imaging may also demonstrate nodularity, atrophy of the
entire liver, atrophic right lobe, hypertrophied left lobe, a
dilated portal vein (>13mm), collaterals, and spontaneous
splenorenal shunt—ﬁndings all consistent with the presence
of cirrhosis [10].
When ascites is present in association with signs of cir-
rhosis and portal hypertension, advanced liver disease is es-
sentiallyassured.Gallbladderandbowelwalledemaarecom-
mon when ascites is present, due simply to abdominal ede-
ma; these ﬁnding do not imply the presence of signiﬁcant
gallbladder or bowel pathology.
Due to these patients’ frequent risk factors for cancer,
they may have malignancy-related ascites contributing to
ﬂuid retention in addition to cirrhosis [11].
Some patients with cirrhosis do not know that they
have it and do not seek medical attention until they have
developed a complication of advanced hepatocellular carci-
noma, such as malignant portal vein thrombosis. This in
turnmaybemanifestedbynew-onsetascitesotvaricealhem-
orrhage. Ascites and/or variceal hemorrhage can be the
clinical complications that lead to the request for the CT or
ultrasound.
Although magnetic resonance imaging may be the most
sensitive modality in detecting hepatocellular carcinomas, it
may be too sensitive in detecting dysplastic nodules and may
lead to more confusion than clarity [12]. Local equipment,
expertise on the part of the radiologist, and patient coopera-
tionwithbreathholdingallimpactimagequality.Alsoitmay
be diﬃcult to obtain due to its high cost compared to other
modalities. In general this author reserves this modality to
further clarify focal lesions that are detected on ultrasound
or CT.
7.SensitivitytoCoumadin
Patients with cirrhosis can be unusually sensitive to the an-
ticoagulant eﬀects of coumadin. This author has seen a
patientwhowassupratherapeuticwithasubduralhematoma
taking only 0.5mg of coumadin ﬁves days per week. Pa-
tients who are therapeutic or supratherapeutic on unusually
low doses of coumadin should be suspected of having cir-
rhosis.
8. Referral
If there is evidence of cirrhosis based on history, physical
examination, laboratory testing, or imaging, referral of the
patient to a hepatologist or liver-focused gastroenterologist
maybeinorder.Thesesubspecialistsaremostadeptinprior-
itizing the many problems of the patients with cirrhosis, and
in treating those problems, with the lowest risk of harming
the patient in the process.
Table 2: General advice regarding the care of patients with cirrho-
sis.
Total abstinence from alcohol
Consider baclofen to reduce/eliminate alcohol craving and
alcohol use
Minimize medications, herbals, and food supplements
Avoid overweight/obesity
No prophylactic diets
Avoid raw oysters and clams
Consider vitamin D
Avoid lifting >40 pounds (18kilograms)
Treat nuisance symptoms as needed
Screen for treatable components to liver injury, varices, and
hepatocellular carcinoma
Avoid sedatives, narcotics, and tranquilizers
Use acetaminophen and tramadol and avoid nonsteroidal anti-
inﬂammatory drugs
Avoid hepatotoxins and nephrotoxins
C a r e f u l l yw e i g hr i s k sv e r s u sb e n e ﬁ t so fa l li n v a s i v ep r o c e d u r e s ,
especially surgery
Use MELD 9 to estimate operative mortality
Do no harm
9.LiverBiopsy
Most patients with cirrhosis do not need a liver biopsy. The
causes(s) and severity are usually evident without the need
for histologic examination. Risks must be weighed against
beneﬁts. The biopsy is performed only if it will have an im-
pact on treatment. Transjugular biopsy with pressures is pre-
ferable when ascites and/or coagulopathy are present.
10. Liver Transplantation
Liver transplantation can be considered, based on psychoso-
cial issues, severity of liver failure, and comorbidities. Early
referral is preferable to late referral in order to assure insur-
ance coverage for transplant, reduction in comorbidities,
change in life style, and screening for treatable disease. An
elective evaluation is preferable to an emergent evaluation
after the patient sustains a major deterioration.
11. General Advice to Patients
Many patients with cirrhosis have multiple insults to the
liver including alcohol use/abuse. Abstinence from alcohol
can dramatically improve their overall condition, even in the
continuedpresenceofchronichepatitisCand/orobesity[13]
(Table 2). Many patients with alcoholic liver disease can have
alcoholic hepatitis superimposed on cirrhosis [14]. Patients
who have a major component of alcoholic hepatitis can
recompensate dramatically with abstinence. Ascites that has
been refractory to diuretics can become diuretic responsive
again and can even disappear such that diuretics can be
discontinued. Chronic hepatitis B with decompensation and
treatment with an antiviral is essentially the only other form
of liver failure in which this sequence can occur.4 International Journal of Hepatology
Abstinence is key to survival of the patient with decom-
pensated alcoholic liver disease; those who continue to drink
are all dead within three years [15]. In stark contrast, ap-
proximately3/4ofthosewhototallyabstaincansurvivethree
years [15].
Baclofen, 5mg orally thrice daily for three days, then
10mg orally thrice daily for a total of 90 days, has been
shown in a carefully performed randomized, double-blind,
controlled trial to dramatically decrease alcohol craving and
alcoholuse,speciﬁcallyinpatientswithalcoholicliverdisease
[16]. Prior trials of drugs to reduce alcohol use speciﬁcally
excluded patients with liver disease. This author has had very
good success with this drug in safely reducing and actually
eliminating alcohol consumption with treatment duration
greater than twelve months [14, 17].
12.Diet
Diet is a cause of confusion and controversy in cirrhosis.
Obesity speeds hepatitis C liver injury, speeds alcoholic liver
injury and can cause cirrhosis in the absence of other insults
[8, 18] .O b e s i t yi sb e s tp r e v e n t e d .O n c ei ti sp r e s e n ta n dt h e
patient has developed cirrhosis, the fat tends to disappear
from the liver and patients regularly spontaneously lose
weight [8]. At this late stage it may be too late for further
weight reduction to be beneﬁcial to the liver. We need pro-
spectively collected data regarding this topic.
It is reasonable to advise patients with risk factors for
cirrhosis to maintain their body-mass index <25 or at least
<30 to minimize the risk of fatty liver contributing to further
liver damage.
“Prophylactic” sodium or protein restriction is not data
supported and could aggravate or induce malnutrition. So-
dium restriction should only be advised once ﬂuid retention
has developed. A daily 2000mg sodium restriction is the
most data supported and can be followed without purchase
of special foods [19]. Fluid restriction is not necessary unless
the serum sodium drops below 120mmol/L; even then its
utility is not data supported [19]. Protein restriction is
almost never needed—only when a patient has extremely
severe hepatic encephalopathy that is unresponsive to two
drugs and restriction of meat protein. This only occurs after
surgical, interventional radiologic, or spontaneous porta-
caval shunts, in this author’s experience.
13.Raw OystersandClams
This author gives his patients with cirrhosis written instruc-
tions not to eat raw shellﬁsh. Establishments in California
that sell raw shellﬁsh must display a visible sign warning
patientswithliverdiseasethatthesefoodscancauseaserious
and potentially fatal infection. This infection is due to Vibrio
vulniﬁcus. Patients with cirrhosis are unusually vulnerable to
this infection [20]. This author has seen only one survivor
who had to have both legs amputated.
14.Herbals
Many people are taking herbals or food supplements for
health maintenance or for self-treatment of disease. This
practice can cause harm to the liver since some of these
agents are hepatotoxic. These substances are not regulated
by the Food and Drug Administration (FDA), may not be
pure, and may contain no actual active ingredient. One of
the few data-supported agents that may beneﬁt patients with
cirrhosis is vitamin D. Patients with cirrhosis are usually
deﬁcient in vitamin D; deﬁciency correlates with worse dis-
ease severity [21, 22]. Measurement of the vitamin D level
and supplementation to achieve a normal level may help in
many ways to improve the health of these patients.
It is possible that milk thistle can beneﬁt patients with
hepatitis C or fatty liver. The ongoing National Institutes of
Health trial will eventually answer this question. If this trial
is positive, this drug should be FDA approved, available in a
pure, regulated form, and insurance should pay for it.
15.HeavyLifting
When a patient bears down and does a Valsalva maneuver to
pick up something heavy, he/she can dramatically increase
the pressure in esophageal varices. These varices can sud-
denly bleed. This author has seen this happen many times.
This author advises patients with esophageal varices to limit
the weight that they lift to 40 pounds (18 kilograms).
16.NuisanceSymptoms
Many patients with cirrhosis have insomnia, muscle cramps,
nausea, pruritus, unintentional weight loss, and meralgia
paresthetica. Patients may not spontaneously complain of
these symptoms but regularly conﬁrm their presence when
asked.
17.Sedatives
Many physicians prescribe standard sedatives for insomnia
with or without knowing that the patient has cirrhosis.
Sedatives can unmask the patient’s tendency for hepatic en-
cephalopathy and can even cause frank coma. It is useful to
order a urine drug screen when a patient with evidence of
cirrhosis is in the emergency department with mental status
change.Prescriptionsedatives(whichmayormaynotbelong
to the patient) or sedating street drugs may be detected. Dis-
continuing these agents can solve the patient’s confusion
problem.
The only drug that has been shown to be eﬀective spe-
cifically for insomnia of cirrhosis is hydroxyzine at 25mg at
night [23]. This author has been using trazodone 100mg at
night for patients with cirrhosis and insomnia; this drug can
help with insomnia and can also treat depression that may be
overt or covert in these patients.
18. Muscle Cramps
Muscle cramps are common is patients with cirrhosis,
especially once ﬂuid retention develops. Many patients have
muscle cramps despite normokalemia. Quinidine has been
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the risk of sudden death from quinidine probably outweighs
the beneﬁt of this drug. Quinine sulfate works well in this
author’s experience but is no longer available over the coun-
ter and is not FDA approved for muscle cramps any longer.
Patients can get quinine sulfate in tonic water. This author
advises them to drink a glass or two per day and then con-
tinue this as needed to prevent the cramps.
19.Nausea
Nausea of liver disease, especially the patient with deep
jaundice, is a nuisance symptom that was well controlled
with cisapride. However, this drug is essentially not available
any longer either. Metoclopramide can be helpful in control-
ling nausea and seems more eﬀective than ondansetron in
patients with liver disease.
20.Pruritus
Pruritus is most characteristic of primary biliary cirrhosis
but can be present in any patient with jaundice and even
in anicteric patients with hepatitis C. Cholestyramine is the
most eﬀective treatment; however, patients do not like to
take it, and there are drug/drug interactions. It should be
taken 1 hour before or 2 hours after other drugs to maximize
absorption of those drugs. Sertraline has been shown to
decrease pruritus in primary biliary cirrhosis in a random-
ized trial [25].
21. MuscleWeight Loss
Many patients with cirrhosis lose body weight including
muscle weight when they decompensate. Two cans of nutri-
tional supplement after 9pm have been shown to increase
muscle mass in cirrhosis in a randomized trial [26].
22.MeralgiaParesthetica
Numbness and tingling of the lateral thigh can be due to
injury to the lateral femoral cutaneous nerve, due to pressure
induced by ascites. This meralgia paresthetica is a cause of
concern among patients and a cause of confusion among
physicians. It can improve with control of ﬂuid overload and
does not warrant speciﬁc treatment otherwise [27].
23. Screeningand Prevention
Patients with suspected or proven cirrhosis should be
screened for causes of cirrhosis and for complications of cir-
rhosis. Preventative measures and treatments should be pro-
vided when appropriate.
Body Mass Index (BMI). As mentioned previously many pa-
tients with cirrhosis have more than one liver insult. This
author has a new patient consult preprinted form that
includesdetailssuchasnumberofyearsofBMI>25,number
of years of BMI >30, and number of years of diabetes or
prediabetes. We measure the patient’s height and weight.
This author has given up asking about height. Patients are
embarrassedwhentheirmeasuredheightisessentiallyalways
shorter than their stated height—even six inches! These de-
tails provide some clues regarding the possibility of NASH
playing a role in causing cirrhosis.
24.Alcohol
This author also asks patients when they ﬁrst started drink-
ing, what they drink, how many drinks daily for how many
years, as well as how many public intoxication charges and
how many arrests for driving under the inﬂuence of alcohol
they have had. These details provide evidence regarding the
role of alcohol in causing cirrhosis.
25. Risk Factors for Chronic Hepatitis
This author asks about risk factors for chronic hepatitis,
including intravenous drug use (even once), cocaine use,
transfusion prior to 1992, dialysis, birth in a country where
hepatitis B is endemic, homosexual behavior, carrier in the
family, tattoos, and acupuncture.
Blood should be tested for hepatitis C antibody, total
antibody for hepatitis A, and three tests for hepatitis B, in-
cludingsurfaceantigen,totalcoreantibody,andsurfaceanti-
body.ThosewhoarenotimmunetohepatitisAandBshould
be vaccinated for those viruses to prevent acute on chronic
liver failure.
26.Other Serologic Testing
Testing for autoantibodies, iron, ceruloplasmin, and alpha-1
antitrypsin phenotype should be performed, depending on
the age of the patient and other risk factors.
27. Varices and Hepatocellular Carcinoma
Allpatientswithcirrhosisshouldbeconsideredforscreening
for esophageal varices by upper endoscopy and for hepato-
cellular carcinoma. This author used to avoid screening very
elderly patients, that is, those >80 years of age. However,
variceal hemorrhage can occur in this age group. Hemor-
rhage is better prevented through endoscopy and beta block-
ade rather than being treated after it occurs. When large
varices are detected in patients who have not bled, a beta
blocker should be prescribed; survival is improved by this
strategy [28]. The details of screening for hepatocellular car-
cinoma are somewhat controversial. The practice guideline
recommends ultrasound twice yearly [29]. This author ob-
tains an ultrasound once yearly, a CT once yearly, and alpha
fetoprotein twice yearly. Ultrasound is a very insensitive
modality in detecting this tumor; CT is preferable but in-
volves radiation and potential nephrotoxicity [12]. This
author obtains one of these modalities every six months.
28. Drugs inPatientswith Cirrhosis
28.1. Pain Control. Pain control is a major issue in patients
with cirrhosis. Narcotic use decreases pain threshold; many6 International Journal of Hepatology
prior intravenous narcotic users switch to prescription
narcotics and become “drug seekers,” asking for narcotics
from every physician who they encounter. The “5th vital
sign” is a huge problem in this regard. Forcing physicians by
law to prescribe narcotics when patients claim to have severe
pain has been associated with a dramatic increase in narcotic
use as well as fatal and nonfatal narcotic overdoses [30]. This
author opposes use of narcotics in patients with cirrhosis
unless they have cancer-related pain. The physician who pre-
scribes narcotics liberally can become an “enabler” of the
patient’s addiction.
Narcotics regularly unmask the tendency to HE and ag-
gravate HE. Stopping the narcotic use can eliminate HE or
make it easier to treat. Patients with cirrhosis on methadone
candevelopHEastheircirrhosisworsens;taperingthemeth-
adone dose to zero can help with treatment of their confu-
sion.
Similarly other drugs that cause constipation can aggra-
vateHEandshouldbestoppedwhenHEbecomesaproblem.
28.2. NSAIDs. Nonsteroidal anti-inﬂammatory drugs
(NSAIDs) are poorly tolerated by patients with cirrhosis.
Approximately 1/3 of patients with cirrhosis who bleed from
the upper gut have taken an NSAID within two weeks of the
hemorrhage [31]. This author gives patients with cirrhosis
written instruction not to take a single NSAID pill as long
as they live. A rare patient whose coronary artery disease ex-
ceeds the severity of his cirrhosis may be permitted to take
an 81mg aspirin daily.
28.3. Acetaminophen. Many physicians are confused about
pain control in cirrhosis. Some actually prohibit acetamino-
phen use and recommend NSAIDs instead. This strategy is
simply wrong and regularly harms the patient. Acetamino-
phen is tolerated better by patients with cirrhosis than by
normal healthy people [32]. It is the active metabolite that
is hepatotoxic. This author has been advising patients in
writingfortwodecadesthat4000mgdailyofacetaminophen
is acceptable. There are no data to support a maximum dose
of2000mgdaily[32].Thatdosedoesnotcontrolcontinuous
pain. If pain is not controlled with 4000mg daily, this author
adds tramadol at 50mg thrice daily and occasionally 100mg
thrice daily for a large patient with severe pain. This author
has not seen problems with these doses of these drugs in
patients with cirrhosis.
28.4. Hepatotoxins and Nephrotoxins. The risks versus ben-
eﬁts of every medication must be carefully considered in
patients with cirrhosis. Although patients with cirrhosis do
not have a higher statistical chance of hepatotoxicity from
drugs,theyhaveless“reserve”thanpeoplewithnormallivers
and may develop acute-on-chronic liver failure. Isoniazid
is a notorious example of this phenomenon. Patients with
cirrhosis should be considered for nonisoniazid-based anti-
tuberculosis treatment and the threshold for treating “gray-
zone” patients should be high. Many patients with cirrhosis
are from countries where Bacillus Calmette-Guerin vacci-
nations are given. They may have a false-positive skin test
for tuberculosis. Isoniazid-associated fatal hepatotoxicity is
reported in such patients, even in the absence of cirrhosis
[33].
Patients with cirrhosis and azotemia may not tolerate
intravenous contrast. If the serum creatinine is >1 . 5o re s -
timated clearance is <30 mL/min, it may be prudent to avoid
the contrast. Aminoglycosides are also poorly tolerated by
patients with cirrhosis and should be avoided unless there
is no other option.
29. GeneralPhilosophyofDrugUseinCirrhosis
Oneoftheﬁrstthingsthatthisauthordoeswhenevaluatinga
newconsultpatientistoremovemostofthedrugsfromtheir
list. The fewer drugs, the better. Complicated drug regimens
are regularly abandoned by these patients. This author’s
philosophy is to prescribe only the crucial drugs and stop
the others. Some funding sources only provide six drugs per
month. Prescribing useless/borderline eﬃcacy drugs may
prevent these patients from receiving crucial drugs that keep
them compensated and out of the hospital, such as diu-
retics.
Vitamins other than vitamin D are not data supported
for long-term use in patients who are eating well and do not
havemalabsorption.Alcoholicsusuallyreceivefolateandthi-
amine when hospitalized. However, there is no evidence that
long-term continuation of these drugs is useful. Vitamin K is
given parenterally (intravenously or subcutaneously but not
intramuscularly) to hospitalized patients with coagulopathy.
Oral vitamin K is not well absorbed and is one of the useless
drugs mentioned above.
30.InvasiveProcedures
Minor procedures such as abdominal paracentesis are well
tolerated by patients with cirrhosis even without prophylac-
tic transfusions of plasma or platelets [19]. There is no data-
supported cutoﬀ beyond which these procedures cannot be
done. The risks versus beneﬁts of each procedure must be
carefully considered. The beneﬁts of abdominal paracentesis
almost always outweigh the risks
31. Surgery
Patients with cirrhosis regularly die due to multi-organ
failure after abdominal or thoracic surgical procedures [34,
35]. Cranial and orthopedic surgery may be better tolerated
[34]. Postoperative mortality can be estimated by “MELD
9,” http://www.mayoclinic.org/meld/mayomodel9.html.T o o
often the presence of cirrhosis was not detected preopera-
tively. It may be detected intraoperatively when a nodular
liver and/or large abdominal collateral are seen, or postop-
eratively when jaundice and multi-organ failure develop.
Referring physicians as well as surgeons and anesthesiol-
ogists regularly ignore the clues and signs that should have
been acknowledged and should have led to postponement of
the procedure and hepatology consultation for preoperative
clearance.International Journal of Hepatology 7
When this author is asked to “clear” patients for surgery,
he prints out the MELD 9 estimate of 7-day, 30-day, 90-
day, 1-year and 5-year mortality. He discusses these estimates
with the patient and their family and usually recommends
a minimally invasive procedure instead of the state-of-the-
art maximally invasive procedure. For example, radiation or
laser therapy or fulguration can be given instead of a resec-
tion. The prognosis of many patients with cirrhosis is worse
than their prognosis from the untreated tumor. Symptoms
caused by the tumor and life expectancy from both condi-
tions must be weighed. This author has seen patients un-
dergo fatal resection of a previously treated (radiation and
chemotherapy) colon cancer; there was no residual malig-
nancy in the resected specimen. This is a tragedy that is pre-
ventable by careful evaluation of the risks versus beneﬁts of
surgery and consideration of the possibility that the tumor is
already cured.
32. Conclusions
Many people who have cirrhosis remain undiagnosed.
Careful attention to risk factors for liver disease and clues
to the presence of cirrhosis on history, physical examination,
laboratory testing, and imaging can rule in the presence of
cirrhosis and help avoid harmful treatments. Cirrhosis has
an impact on medication usage and mortality after invasive
procedures. The fewer medications taken by these patients,
the better their outcome. The fewer invasive procedures per-
formed on these patients, the better the outcome. The risks
versus beneﬁts of medication and each procedure must be
carefully weighed. Do no harm is the relevant dictum.
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